Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib for induction and maintenance treatment of newly diagnosed primary central nervous system diffuse large B-cell lymphoma
ChiCTR2100052815Phase 4Recruiting
- Sponsor
- Xinqiao Hospital
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of orelabrutinib in Diffuse Large B-Cell Primary Central Nervous System Lymphoma, sponsored by Xinqiao Hospital. Primary endpoint: overall response rate. Started Dec 2021; status: recruiting.
02
Drugs
orelabrutinib
03
Conditions
Diffuse Large B-Cell Primary Central Nervous System Lymphoma
Beyond the preview
Go deeper on ChiCTR2100052815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100052815.